Drug metabolism and pharmacokinetic (DMPK) scientists are tasked with the determination of various parameters to predict human PK. Their [...]
Hepatotoxicity (liver cell toxicity) is one of the major causes of drug attrition during clinical development and withdrawal post-marketing. [...]
Dr. Benedict Law’s lab is developing nanomaterials for the more efficient delivery of chemotherapy to cancerous tumors in the [...]
Effective today, Visikol has become and is committed to remain a carbon neutral company. While Visikol is a leading [...]
Over the last few years, researchers have begun to transition from using traditional two-dimensional cell culture models for assessing [...]
In this episode of Digital Pathology Today, Visikol CEO Michael Johnson, PhD discusses 3D imaging in digital pathology. We [...]
Over the last five years, Visikol has developed an extensive portfolio of advanced imaging, digital pathology and cell culture [...]
We are pleased to announce that between now and June 30th, 2021, Visikol will be accepting abstract submissions for [...]
In the last few years there has been a significant increase in the number of researchers that want to [...]
At Visikol, our mission is to accelerate the discovery and development of therapeutics through transforming tissues into quantitative data [...]